- Total of 11 presentations highlighting company’s infectious disease program targeted at the most urgent needs in combating resistant organisms
- Includes data on clinical experience with ORBACTIV® (oritavancin) in outpatient infusion center compared to standard-of-care
- In vitro data on meropenem-vaborbactam (formerly known as RPX7009) against clinical isolates of Enterobacteriaceae to be presented
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA. The company’s infectious disease R&D program is targeted at the most deadly and insidious bacterial threats threatening global health.
“As we have heard once again in recent weeks, this time from the AMR final report by Lord O'Neill's UK-based group, there is a global need to accelerate the discovery and development of new agents to treat drug-resistant bacteria”
Investigators will present data on ORBACTIV® (oritavancin) in the single-dose treatment of acute bacterial skin and skin-structure infections (ABSSSIs), including results from an outpatient infusion center. Researchers will also present in vitro activity of ORBACTIV against frequently isolated gram-positive bacteria and clinical isolates, including those with reduced or non-susceptibility to daptomycin and linezolid.
“We are seeing increasing adoption and use of a single, once-only dose of ORBACTIV in the management of ABSSSIs in real-world settings outside the hospital,” said Mike McGuire, Senior Vice President and Co-Leader of the Infectious Diseases Global Innovation Group, The Medicines Company. “Studies supporting this experience are important for validation of the value of this approach for patients and clinicians.”
Company researchers will present in vitro data for the Phase 3 investigational agent CARBAVANCE® (meropenem-vaborbactam) on activity against Enterobacteriaceae isolates recently collected in US hospitals, including carbapenem-resistant Enterobacteriaceae (CRE), which has been identified as an urgent microbial threat by the Centers for Disease Control (CDC). Researchers will also present data on vaborbactam inhibitory activity against a mutation of the KPC gene that affects the activity of some beta-lactamase inhibitors.
In addition, researchers from Monash University and The Medicines Company will present data on the discovery of a novel series of polymyxins from a NIAID-funded research collaboration.
“As we have heard once again in recent weeks, this time from the AMR final report by Lord O'Neill's UK-based group, there is a global need to accelerate the discovery and development of new agents to treat drug-resistant bacteria,” said Michael Dudley, PharmD, Senior Vice President and Head, Health Science R&D, and Co-Leader of the Infectious Diseases Global Innovation Group, The Medicines Company. “The so-called superbugs are major threats globally, and we must find ways to continually to stay one step ahead of these organisms. Our development program is moving quickly and efficiently, and we believe our products and pipeline of ongoing discovery and development programs are among the few but best in industry, and are well-positioned to meet this need.”
A list of key presentations is included below. The complete program of titles and abstracts can be accessed on ASM Microbe 2016 web site at ASMMicrobe.org.
For full article, please click here.
